letter
FREE Daily Email Newsletter
Patheon Invests in Milton Park, UK Facility to Expand Early Development Capabilities in Europe
January 31, 2013 7:03 am | News | CommentsPatheon Inc., a provider of contract development and commercial manufacturing services to the global pharmaceutical industry, today announced plans for additional investment in its Milton Park facility.
Kemwell Announces Successful Pre-NDA US FDA Inspection
January 31, 2013 3:05 am | News | CommentsKemwell Biopharma Pvt. Ltd., a global pharmaceutical contract development and manufacturing company, announced today that its Oral Solids manufacturing facility located in Bangalore, India has successfully completed a U.S. Food and Drug Administration (USFDA) inspection.
Study Sees Prostate Cancer Treatment Side Effects
January 31, 2013 3:01 am | by MARILYNN MARCHIONE,AP Chief Medical Writer | News | CommentsA new study shows how important it is for men to carefully consider treatments for early-stage prostate cancer.
Danish Novo Nordisk Profit Surges
January 31, 2013 2:56 am | News | CommentsDanish pharmaceutical company Novo Nordisk A/S has reported a 23 percent growth in fourth-quarter net profit on strong sales of diabetic drugs and gave a positive outlook as regulators worldwide approved its latest range of insulin products.
Teva Announces Termination of Agreements with CureTech
January 31, 2013 2:54 am | News | CommentsTeva Pharmaceutical Industries Ltd. announced today the termination of its collaboration with CureTech Ltd.
Tapemark Expands Capabilities for Transdermal Patches
January 31, 2013 2:49 am | News | CommentsTapemark has announced the addition of several new capabilities for transdermal patches, including the formulation, blending, and coating steps in the patch manufacturing process.
Parexel Posts Higher Profit, Lifts Outlook
January 30, 2013 3:32 am | News | CommentsPharmaceutical research contractor Parexel International Corp. said on Tuesday that its fiscal second-quarter earnings jumped 65 percent as the company's backlog of contracts grew.
Vertex Swings to Loss on Weak Hep C Drug Sales
January 30, 2013 3:29 am | News | CommentsVertex Pharmaceuticals Inc. swung to a loss in the fourth quarter as doctors turned away from the company's best-selling drug for treating hepatitis C.
FDA Gives New Drug Application Approval to Isis
January 30, 2013 3:27 am | News | CommentsDrug developer Isis Pharmaceuticals Inc. and partner Genzyme announced Tuesday that the U.S. Food and Drug Administration has approved their new drug application for Kynamro, clearing the way for Isis' first drug to reach market.
AbbVie Issues Inaugural Full-Year Outlook for 2013
January 30, 2013 3:24 am | News | CommentsAbbVie delivered strong sales growth with its marketed pharmaceutical products in 2012. The proprietary pharmaceutical segment of Abbott, representing the majority of AbbVie's revenue, grew more than 8 percent globally on an operational basis.
2013 Facility of the Year Awards (FOYA) Winners Announced
January 29, 2013 6:31 am | News | CommentsThe Facility of the Year Awards Judging Panel has named six Category Award Winners in the 2013 Facility of the Year Awards (FOYA) program. The winning projects for 2013 were selected from 27 well-qualified entries.
Metrics Names New VP of Pharmaceutical Development
January 29, 2013 3:19 am | News | CommentsMetrics Inc. has named Dr. Thomas B. “Brad” Gold vice president of pharmaceutical development.
GSK and Biological E. to Develop Combination Vaccine for India and Other Developing Countries
January 29, 2013 3:12 am | News | CommentsGlaxoSmithKline (GSK) and Biological E Limited (Biological E.), an Indian vaccines company, today announced an agreement to form a 50/50 joint venture (JV) for the early stage research and development of a six-in-one combination pediatric vaccine.
Repros Plunges on Testosterone Drug Study Delay
January 29, 2013 3:04 am | News | CommentsShares of Repros Therapeutics Inc. plunged 40 percent Monday after the company said that results from a study of its testosterone drug Androxal will be delayed because it is removing some patients from the trial.
Eli Lilly 4Q Profit Slips But Tops Expectations
January 29, 2013 3:01 am | by TOM MURPHY,AP Business Writer | News | CommentsEli Lilly and Co.'s fourth quarter earnings slipped 4 percent as generic competition continued to eat away at sales of its former best-seller, the antipsychotic Zyprexa, but the drugmaker cut expenses again and growth from other products helped it beat analyst expectations.
Nuvo Research Announces Settlement Agreement with Apotex in PENNSAID Generic Litigation
January 29, 2013 2:54 am | News | CommentsNuvo Research Inc.announced today that it has entered into a settlement agreement with Apotex Inc. and Apotex Corp. (together Apotex) respecting patent infringement litigation brought by Nuvo and Nuvo's U.S. licensing partner, Mallinckrodt Inc. (Mallinckrodt), in response to Apotex's filing of an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w (PENNSAID).
Pfizer Q4 Net Jumps on Sale of Nutrition Business
January 29, 2013 2:51 am | News | CommentsPfizer Inc. says its fourth-quarter profit more than quadrupled, despite competition from generic drugs hurting sales, because of a $4.8 billion gain from selling its nutrition business.
Amneal Partners with Hanmi to Market Nexium® Alternative
January 28, 2013 2:56 am | News | CommentsAmneal Pharmaceuticals, LLC today announced that it has entered into a license and distribution agreement with South Korea-based Hanmi Pharmaceutical Co., Ltd to acquire exclusive distribution rights to Hanmi's new drug application (NDA), currently under FDA review, for esomeprazole strontium delayed-release capsules.
Biogen Idec 2012 Revenue Increases 9% to $5.5B
January 28, 2013 2:53 am | News | CommentsBiogen Idec Inc. has announced full year and fourth quarter 2012 results.
Novartis Europharm Withdraws Marketing-Authorization Application for Ruvise
January 25, 2013 3:07 am | News | CommentsThe European Medicines Agency has been formally notified by Novartis Europharm Ltd of its decision to withdraw its application for a centralized marketing authorization for the medicine Ruvise.
US Hit By New Stomach Bug Spreading Around Globe
January 25, 2013 3:02 am | by MIKE STOBBE,AP Medical Writer | News | CommentsA new strain of stomach bug sweeping the globe is taking over in the U.S., health officials say.
Lawyer: Massachusetts Firm Tied to Meningitis Outbreak Paid Out $70M
January 25, 2013 2:58 am | by JAY LINDSAY,Associated Press | News | CommentsAn attorney for creditors of a pharmacy blamed for a nationwide meningitis outbreak said Thursday that the firm paid out $70 million to company insiders over the last six years.
Orexo Enters Research Agreement with AstraZeneca for Respiratory Disease Program
January 25, 2013 2:50 am | News | CommentsOrexo AB announced today that the company has entered into an agreement with AstraZeneca regarding OX-CLI, a preclinical program for a potential novel treatment of respiratory diseases.
AAIPharma Appoints Senior Director of Parenteral Operations
January 24, 2013 4:44 am | News | CommentsAAIPharma Services Corp., a provider of pharmaceutical product development services, announced today that it has appointed James Fife as the company's senior director of parenteral operations for its manufacturing facility in Charleston, S.C.
Scientists to Resume Work with Lab-Bred Bird Flu
January 24, 2013 3:06 am | by LAURAN NEERGAARD,AP Medical Writer | News | CommentsInternational scientists who last year halted controversial research with the deadly bird flu say they are resuming their work as countries adopt new rules to ensure safety.
